Tandem Diabetes Care Inc. Overview
Tandem Diabetes Care, Inc., a prominent player in the health care equipment and supplies sector, is headquartered in San Diego, United States. The company is dedicated to designing, developing, and commercializing innovative products for individuals with insulin-dependent diabetes. Tandem Diabetes Care primarily serves the medical industry within the United States, offering a range of products aimed at improving the quality of life for those managing diabetes.
Financial Snapshot
As of August 4, 2025, Tandem Diabetes Care’s stock closed at $15.15 on the Nasdaq exchange. The company’s market capitalization stands at approximately $1.04 billion USD. Over the past year, the stock has experienced significant volatility, reaching a 52-week high of $47.60 on September 24, 2024, and a 52-week low of $14.31 on July 20, 2025. The price-to-earnings ratio is currently at -5.44, reflecting the company’s financial performance and market expectations.
Company Background
Tandem Diabetes Care made its initial public offering (IPO) on November 14, 2013, marking its entry into the public market. Since then, the company has focused on expanding its product offerings and enhancing its technological capabilities to better serve its target market. For more detailed information about their products and services, interested parties can visit their official website at www.tandemdiabetes.com .
Market Position
Operating within the health care equipment and supplies industry, Tandem Diabetes Care is committed to innovation and excellence. The company’s focus on insulin-dependent diabetes solutions positions it as a key player in the health care sector, addressing a critical need within the medical community. As the company continues to grow and evolve, it remains dedicated to improving the lives of those affected by diabetes through cutting-edge technology and comprehensive care solutions.